 | |
- close
- close
Business Wire
Jan 11
Comment
Gentium S.p.A. (Nasdaq: GENT) today announced that it has amended its existing License and Supply and Cost Sharing Agreements with Sigma-Tau Pharmaceuticals, Inc. for the development and commercialization of Defibrotide in North America, Central
StreetInsider.com
Dec 17
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Gentium+%28GENT%29+Appoints+Dr.+Khalid+Islam+to+Chairman/5191827.html for the full story.
Business Wire
Dec 8
Comment
Gentium S.p.A. (NASDAQ: GENT) today announced final clinical trial results from the Company’s Phase II/III Pediatric Prevention trial and Phase III Treatment trial for Defibrotide of Hepatic Veno-Occlusive Disease (VOD), which were presented at the
Business Wire
Dec 7
Comment
Gentium S.p.A. (Nasdaq: GENT) today announced the resignation of Dr. Francesco Bellini as Chairman and a member of Gentium’s Board of Directors, who indicated that his other business commitments prevented him from continuing to devote adequate time
Business Wire
Nov 30
Comment
Gentium S.p.A. (NASDAQ: GENT) (the “Company”) today reported financial results for the quarter ended September 30, 2009. Financial Highlights Gentium S.p.A., or the Company, reports its financial condition and operating results using U.S.
Business Wire
Nov 9
Comment
Gentium S.p.A. (Nasdaq: GENT) announced today the members of its new Board of Directors and the appointment of an Interim CEO. The new Board is comprised of the following seven members, who were elected at the recent ordinary meeting of shareholders:
FierceBiotech
Aug 19
Comment
Italy's Gentium saw its shares sag on the news that its experimental therapy to treat the blockage of small veins in the liver failed the primary and secondary endpoints of a late-stage trial.
The veno-occlusive disease treatment defibrotide...
Suggest other news sources for this topic
Thank you for your suggestion
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
GENT AT A GLANCE
References
| ||||||
|
|
